Correlations of Cognitive Function with Serum Levels of Homocysteine, Sex Hormone Binding Globulin, and Leptin in Patients with Schizophrenia

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2024 Nov 18

PMID 39554652

Authors

Yunqiang Xu

Xiulian Qian

Minqiao Zhang

Ming Liang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the correlations of cognitive function with serum levels of homocysteine (Hcy), sex hormone binding globulin (SHBG), and leptin in patients with schizophrenia.

Methods: This was retrospective study. This study included 58 patients with schizophrenia (SCZ) as observation group and 60 clinically healthy individuals as control group admitted to Xiangshan County Hospital of Traditional Chinese Medicine Medical and Health Group Third Hospital from March 2022 to June 2023. Serum levels of Hcy, SHBG, and leptin in the two groups were measured, and Pearson correlation analysis was conducted to investigate the correlations between the Hcy, SHBG, and leptin levels and the psychiatric symptoms and cognitive function in the observation group.

Results: The Hcy and SHBG levels in the observation group were significantly higher than those in the control group (0.05, respectively), and the leptin level was lower than that in the control group (0.05). The observation group scored significantly lower than the control group for each dimension of the MCCB (0.05, respectively). In the observation group, Hcy was positively correlated with negative symptoms and the PANSS total score (0.05, respectively) and was negatively correlated with scores for the leptin was negatively correlated with negative symptoms and the PANSS total score (0.05, respectively) and was positively correlated with scores for speed of processing (SOP), WMS-III, BVMT, and MSCEIT (0.05, respectively).

Conclusions: Increased levels of Hcy and SHBG and decreased leptin are strongly associated with the occurrence of cognitive impairment in SCZ cases. Therefore, clinical observation and monitoring of these markers can help identify changes in patient conditions.

References

Yazici E, Mutu Pek T, Guzel D, Yazici A, Ciner O, Erol A . Klotho, vitamin D and homocysteine levels during acute episode and remission periods in schizophrenia patients. Nord J Psychiatry. 2019; 73(3):178-184. DOI: 10.1080/08039488.2019.1582697. View

Cakici N, Bot M, Lamers F, Janssen T, van der Spek P, de Haan L . Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis. Eur Neuropsychopharmacol. 2019; 29(7):835-846. DOI: 10.1016/j.euroneuro.2019.05.010. View

Fakorede O, Ogunwale A, Akinhanmi A . Disability among patients with schizophrenia: A hospital-based study. Int J Soc Psychiatry. 2019; 66(2):179-187. DOI: 10.1177/0020764019894608. View

Koch E, Rosenthal B, Lundquist A, Chen C, Kauppi K . Interactome overlap between schizophrenia and cognition. Schizophr Res. 2020; 222:167-174. DOI: 10.1016/j.schres.2020.06.002. View

Battle D . Diagnostic and Statistical Manual of Mental Disorders (DSM). Codas. 2014; 25(2):191-2. DOI: 10.1590/s2317-17822013000200017. View

Sade Yazdi D, Laor Bar-Yosef D, Adsi H, Kreiser T, Sigal S, Bera S . Homocysteine fibrillar assemblies display cross-talk with Alzheimer's disease β-amyloid polypeptide. Proc Natl Acad Sci U S A. 2021; 118(24). PMC: 8214689. DOI: 10.1073/pnas.2017575118. View

Herrero P, Contador I, Stern Y, Fernandez-Calvo B, Sanchez A, Ramos F . Influence of cognitive reserve in schizophrenia: A systematic review. Neurosci Biobehav Rev. 2019; 108:149-159. DOI: 10.1016/j.neubiorev.2019.10.019. View

McCleery A, Nuechterlein K . Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations . Dialogues Clin Neurosci. 2019; 21(3):239-248. PMC: 6829172. DOI: 10.31887/DCNS.2019.21.3/amccleery. View

Xu W, Su B, Shen X, Bi Y, Tan C, Li J . Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease. Aging (Albany NY). 2020; 12(14):14528-14541. PMC: 7425468. DOI: 10.18632/aging.103497. View

10.

Wojciak P, Rybakowski J . Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia. Psychiatr Pol. 2018; 52(2):185-197. DOI: 10.12740/PP/70610. View

11.

Sahin G, Luis Rodriguez-Llamas J, Dillon C, Medina I, Appleyard S, Gaiarsa J . Leptin increases GABAergic synaptogenesis through the Rho guanine exchange factor β-PIX in developing hippocampal neurons. Sci Signal. 2021; 14(683). PMC: 8382067. DOI: 10.1126/scisignal.abe4111. View

12.

Esnafoglu E, Deniz Ozturan D . The relationship of severity of depression with homocysteine, folate, vitamin B12, and vitamin D levels in children and adolescents. Child Adolesc Ment Health. 2020; 25(4):249-255. DOI: 10.1111/camh.12387. View

13.

Richetto J, Meyer U . Epigenetic Modifications in Schizophrenia and Related Disorders: Molecular Scars of Environmental Exposures and Source of Phenotypic Variability. Biol Psychiatry. 2020; 89(3):215-226. DOI: 10.1016/j.biopsych.2020.03.008. View

14.

Di Meco A, Li J, Pratico D . Dissecting the Role of 5-Lipoxygenase in the Homocysteine-Induced Alzheimer's Disease Pathology. J Alzheimers Dis. 2017; 62(3):1337-1344. PMC: 5869997. DOI: 10.3233/JAD-170700. View

15.

Chen S, Wang Q, Han B, Wu J, Liu D, Zou J . Effects of leptin-modified human placenta-derived mesenchymal stem cells on angiogenic potential and peripheral inflammation of human umbilical vein endothelial cells (HUVECs) after X-ray radiation. J Zhejiang Univ Sci B. 2020; 21(4):327-340. PMC: 7183445. DOI: 10.1631/jzus.B1900598. View

16.

Hamilton K, Harvey J . The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease. Pharmaceuticals (Basel). 2021; 14(1). PMC: 7827292. DOI: 10.3390/ph14010052. View

17.

Lepock J, Mizrahi R, Korostil M, Bagby R, Pang E, Kiang M . Event-Related Potentials in the Clinical High-Risk (CHR) State for Psychosis: A Systematic Review. Clin EEG Neurosci. 2018; 49(4):215-225. DOI: 10.1177/1550059418755212. View

18.

Pelka-Wysiecka J, Wronski M, Bienkowski P, Murawiec S, Samochowiec A, Samochowiec J . Odors identification differences in deficit and nondeficit schizophrenia. Pharmacol Rep. 2016; 68(2):390-5. DOI: 10.1016/j.pharep.2015.11.001. View

19.

Peng S, Liang C, Deng S, Fu Y . Study on the clinical correlation between the expression of serum TNF-α and iNOS as well as cognitive impairment and disease burden in patients with schizophrenia. Pak J Med Sci. 2022; 38(7):1838-1843. PMC: 9532673. DOI: 10.12669/pjms.38.7.5326. View

20.

Charlson F, Ferrari A, Santomauro D, Diminic S, Stockings E, Scott J . Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr Bull. 2018; 44(6):1195-1203. PMC: 6192504. DOI: 10.1093/schbul/sby058. View